Ionis Pharmaceuticals, Inc. Insider Trading

IONS

Last 12 months

Insiders bought $1.06M and sold $117M on the open market.

81% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer Brett P Monia sold $5.21M on Jan 30, 18% of their stake, outside a plan.

Net open-market

−$116M

1 buy · 66 sales

Under a 10b5-1 plan

81%

of the value sold

Insiders who bought / sold

1 / 19

executives and directors

Last open-market buy

Jul 2026

Jul 31, 2026

Get an email when IONS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 16	Shannon L. Devers EVP, Chief Human Resources Ofc	SoldNo plan	1,357	$43.54	59K	7.1%	Form 4
Oct 16	Eric Swayze EVP Research	SoldNo plan	53	$43.54	2K	0.2%	Form 4
Jul 30 – 31	Michael R Hayden Director	Bought 2 parts	20,000	$52.94 average	$1.06M	34%	Form 4
Jul 7	C Frank Bennett EVP, Chief Scientific Officer	Sold10b5-1 plan 2 parts	20,536	$84.95 average	$1.74M	19%	Form 4
Jul 7	Allene M. Diaz Director	Sold10b5-1 plan	10,111	$85.42	864K	73%	Form 4
Jul 7	Holly B. Kordasiewicz EVP, Chief Development Officer	Sold10b5-1 plan	362	$84.30	31K	1.6%	Form 4
Jul 1	Joseph Klein III Director	Sold10b5-1 plan 2 parts	11,518	$79.04 average	910K	51%	Form 4
Jun 26	Joseph Baroldi EVP, Chief Business Officer	Sold10b5-1 plan	5,635	$80.16	452K	9.6%	Form 4
Jun 26	Patrick R. O'Neil EVP CLO & General Counsel	Sold10b5-1 plan	3,069	$80.00	246K	4.8%	Form 4
Jun 26	Eugene Schneider EVP, Chf Clinical Develop Ofcr	Sold10b5-1 plan	26,000	$81.05	$2.11M	25%	Form 4
Jun 24 – 26	Brett P Monia Chief Executive Officer	Sold10b5-1 plan 3 parts	85,637	$79.70 average	$6.83M	26%	Form 4
Jun 25	Eric Swayze EVP Research	Sold10b5-1 plan	10,602	$79.18	839K	32%	Form 4
Jun 15	Spencer R Berthelsen Director	Sold10b5-1 plan	8,000	$73.49	588K	4.9%	Form 4
Jun 12	Holly B. Kordasiewicz EVP, Chief Development Officer	Sold10b5-1 plan 2 parts	60,846	$73.40 average	$4.47M	73%	Form 4
Jun 1	Spencer R Berthelsen Director	Sold10b5-1 plan	8,000	$75.67	605K	4.9%	Form 4
May 13 – 14	Brett P Monia Chief Executive Officer	Sold10b5-1 plan 2 parts	4,536	$78.49 average	356K	1.8%	Form 4
May 4	Joseph Loscalzo Director	Sold10b5-1 plan 2 parts	77,289	$75.06 average	$5.8M	68%	Form 4
May 1	Joseph Klein III Director	Sold10b5-1 plan 2 parts	10,111	$73.51 average	743K	48%	Form 4
Apr 28	Joseph Baroldi EVP, Chief Business Officer	Sold10b5-1 plan	1,626	$71.79	117K	3.2%	Form 4
Apr 16	Kyle Jenne EVP, Chf GL Pdt Str Ofcr	SoldNo plan	4,902	$75.17	368K	17%	Form 4
Apr 16	Brian Birchler EVP, Corp and Development Ops	SoldNo plan	973	$75.04	73K	1.4%	Form 4
Apr 16	Joseph Baroldi EVP, Chief Business Officer	SoldNo plan	5,619	$74.56	419K	9.9%	Form 4
Apr 15	B Lynne Parshall Director	Sold10b5-1 plan 2 parts	5,000	$76.27 average	381K	8.9%	Form 4
Apr 2	Shannon L. Devers EVP, Chief Human Resources Ofc	Sold10b5-1 plan	6,193	$74.05	459K	27%	Form 4
Apr 1	Joseph Klein III Director	Sold10b5-1 plan 2 parts	22,321	$75.54 average	$1.69M	67%	Form 4
Mar 19	Eugene Schneider EVP, Chf Clinical Develop Ofcr	Sold10b5-1 plan	5,812	$70.97	412K	8.3%	Form 4
Mar 16 – 17	Elizabeth L Hougen EVP, Finance & CFO	Sold10b5-1 plan 3 parts	225,220	$72.43 average	$16.3M	73%	Form 4
Mar 9 – 10	Brett P Monia Chief Executive Officer	Sold10b5-1 plan 5 parts	160,773	$75.35 average	$12.1M	40%	Form 4
Mar 10	Kyle Jenne EVP, Chf GL Pdt Str Ofcr	Sold10b5-1 plan 2 parts	37,277	$75.85 average	$2.83M	69%	Form 4
Mar 9	Patrick R. O'Neil EVP CLO & General Counsel	Sold10b5-1 plan	10,148	$75.25	764K	14%	Form 4
Mar 3 – 4	Joseph Loscalzo Director	Sold10b5-1 plan 2 parts	1,032	$80.27 average	83K	2.8%	Form 4
Mar 3 – 4	Joseph Baroldi EVP, Chief Business Officer	Sold10b5-1 plan 5 parts	6,659	$79.74 average	531K	12%	Form 4
Mar 3	Joseph Klein III Director	Sold10b5-1 plan 3 parts	21,332	$79.51 average	$1.7M	66%	Form 4
Mar 3	Allene M. Diaz Director	Sold10b5-1 plan 3 parts	54,878	$79.35 average	$4.35M	94%	Form 4
Mar 3	Shannon L. Devers EVP, Chief Human Resources Ofc	Sold10b5-1 plan 3 parts	20,106	$79.40 average	$1.6M	47%	Form 4
Mar 3	C Frank Bennett EVP, Chief Scientific Officer	Sold10b5-1 plan 3 parts	85,089	$79.23 average	$6.74M	51%	Form 4
Feb 13	Eric Swayze EVP Research	Sold10b5-1 plan 2 parts	15,642	$81.76 average	$1.28M	33%	Form 4
Feb 11	B Lynne Parshall Director	Sold10b5-1 plan	5,000	$82.72	414K	8.2%	Form 4
Feb 6	Brett P Monia Chief Executive Officer	Sold10b5-1 plan	29,430	$85.79	$2.52M	10%	Form 4
Jan 30	Eric Swayze EVP Research	SoldNo plan	6,179	$82.93	512K	11%	Form 4

Oct 16No plan
Shannon L. Devers
EVP, Chief Human Resources Ofc · sold 1,357 at $43.54
59K
7.1% of stake
Oct 16No plan
Eric Swayze
EVP Research · sold 53 at $43.54
2K
0.2% of stake
Jul 30 – 31
Michael R Hayden
Director · bought 20,000 at avg $52.94
$1.06M
34% of stake
Jul 710b5-1 plan
C Frank Bennett
EVP, Chief Scientific Officer · sold 20,536 at avg $84.95
$1.74M
19% of stake
Jul 710b5-1 plan
Allene M. Diaz
Director · sold 10,111 at $85.42
864K
73% of stake
Jul 710b5-1 plan
Holly B. Kordasiewicz
EVP, Chief Development Officer · sold 362 at $84.30
31K
1.6% of stake
Jul 110b5-1 plan
Joseph Klein III
Director · sold 11,518 at avg $79.04
910K
51% of stake
Jun 2610b5-1 plan
Joseph Baroldi
EVP, Chief Business Officer · sold 5,635 at $80.16
452K
9.6% of stake
Jun 2610b5-1 plan
Patrick R. O'Neil
EVP CLO & General Counsel · sold 3,069 at $80.00
246K
4.8% of stake
Jun 2610b5-1 plan
Eugene Schneider
EVP, Chf Clinical Develop Ofcr · sold 26,000 at $81.05
$2.11M
25% of stake
Jun 24 – 2610b5-1 plan
Brett P Monia
Chief Executive Officer · sold 85,637 at avg $79.70
$6.83M
26% of stake
Jun 2510b5-1 plan
Eric Swayze
EVP Research · sold 10,602 at $79.18
839K
32% of stake
Jun 1510b5-1 plan
Spencer R Berthelsen
Director · sold 8,000 at $73.49
588K
4.9% of stake
Jun 1210b5-1 plan
Holly B. Kordasiewicz
EVP, Chief Development Officer · sold 60,846 at avg $73.40
$4.47M
73% of stake
Jun 110b5-1 plan
Spencer R Berthelsen
Director · sold 8,000 at $75.67
605K
4.9% of stake
May 13 – 1410b5-1 plan
Brett P Monia
Chief Executive Officer · sold 4,536 at avg $78.49
356K
1.8% of stake
May 410b5-1 plan
Joseph Loscalzo
Director · sold 77,289 at avg $75.06
$5.8M
68% of stake
May 110b5-1 plan
Joseph Klein III
Director · sold 10,111 at avg $73.51
743K
48% of stake
Apr 2810b5-1 plan
Joseph Baroldi
EVP, Chief Business Officer · sold 1,626 at $71.79
117K
3.2% of stake
Apr 16No plan
Kyle Jenne
EVP, Chf GL Pdt Str Ofcr · sold 4,902 at $75.17
368K
17% of stake
Apr 16No plan
Brian Birchler
EVP, Corp and Development Ops · sold 973 at $75.04
73K
1.4% of stake
Apr 16No plan
Joseph Baroldi
EVP, Chief Business Officer · sold 5,619 at $74.56
419K
9.9% of stake
Apr 1510b5-1 plan
B Lynne Parshall
Director · sold 5,000 at avg $76.27
381K
8.9% of stake
Apr 210b5-1 plan
Shannon L. Devers
EVP, Chief Human Resources Ofc · sold 6,193 at $74.05
459K
27% of stake
Apr 110b5-1 plan
Joseph Klein III
Director · sold 22,321 at avg $75.54
$1.69M
67% of stake
Mar 1910b5-1 plan
Eugene Schneider
EVP, Chf Clinical Develop Ofcr · sold 5,812 at $70.97
412K
8.3% of stake
Mar 16 – 1710b5-1 plan
Elizabeth L Hougen
EVP, Finance & CFO · sold 225,220 at avg $72.43
$16.3M
73% of stake
Mar 9 – 1010b5-1 plan
Brett P Monia
Chief Executive Officer · sold 160,773 at avg $75.35
$12.1M
40% of stake
Mar 1010b5-1 plan
Kyle Jenne
EVP, Chf GL Pdt Str Ofcr · sold 37,277 at avg $75.85
$2.83M
69% of stake
Mar 910b5-1 plan
Patrick R. O'Neil
EVP CLO & General Counsel · sold 10,148 at $75.25
764K
14% of stake
Mar 3 – 410b5-1 plan
Joseph Loscalzo
Director · sold 1,032 at avg $80.27
83K
2.8% of stake
Mar 3 – 410b5-1 plan
Joseph Baroldi
EVP, Chief Business Officer · sold 6,659 at avg $79.74
531K
12% of stake
Mar 310b5-1 plan
Joseph Klein III
Director · sold 21,332 at avg $79.51
$1.7M
66% of stake
Mar 310b5-1 plan
Allene M. Diaz
Director · sold 54,878 at avg $79.35
$4.35M
94% of stake
Mar 310b5-1 plan
Shannon L. Devers
EVP, Chief Human Resources Ofc · sold 20,106 at avg $79.40
$1.6M
47% of stake
Mar 310b5-1 plan
C Frank Bennett
EVP, Chief Scientific Officer · sold 85,089 at avg $79.23
$6.74M
51% of stake
Feb 1310b5-1 plan
Eric Swayze
EVP Research · sold 15,642 at avg $81.76
$1.28M
33% of stake
Feb 1110b5-1 plan
B Lynne Parshall
Director · sold 5,000 at $82.72
414K
8.2% of stake
Feb 610b5-1 plan
Brett P Monia
Chief Executive Officer · sold 29,430 at $85.79
$2.52M
10% of stake
Jan 30No plan
Eric Swayze
EVP Research · sold 6,179 at $82.93
512K
11% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IONS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with IONS

CompareIntrinsic value

CORTCorcept Therapeutics Incorporated

$77.59-5.30%56

SUPNSupernus Pharmaceuticals Inc.

$28.21+0.21%44

COLLCollegium Pharmaceutical Inc.

$23.56-0.72%98

TGTXTG Therapeutics, Inc.

$61.63+1.45%57

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

AXSMAxsome Therapeutics, Inc.

$137.00-1.87%10

EBSEmergent BioSolutions Inc.

$5.90-5.60%37

ANIPAni Pharmaceuticals Inc.

$72.89+0.84%85

Held by ETFs

IONS is in 105 US ETFs. The largest of them, with IONS's weight in each:

Spot a number that looks wrong? Check it in IONS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IONS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.